SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rezolve AI Plc operates in the mobile commerce industry with its cutting-edge engagement platform powered by artificial intelligence and machine learning. It develops AI-based mobile commerce and engagement solutions, simplifying the purchasing process by providing relevant information and facilitating seamless transactions with a single tap. The company enables retailers, brands, and manufacturers to create dynamic connections with consumers across mobile and desktop devices. Rezolve Ai was founded in 2016 and is headquartered in London, the United Kingdom.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI ($RZLV) is trending due to a significant rebound following a period of intense short selling and recent earnings. Community members are actively discussing the potential for a short squeeze, citing high short interest and positive analyst ratings, and celebrating the stock's resilience amid market volatility.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

ASTS is trending as investors react to the company's announcement regarding the completion of its BlueBird 6 satellite and the planned launch schedule, generating excitement about upcoming milestones. The community is buzzing with bullish sentiment, anticipating new all-time highs and significant long-term growth potential. Some traders are closely monitoring short positions and expecting a potential squeeze.

Bakkt Holdings, Inc. engages in the intersection of cryptoassets, loyalty and rewards, and payments. It also provides a platform to expand payment offerings, create new revenue streams, and increase customer loyalty. The company was founded in 2018 and is headquartered in Alpharetta, GA.

Bakkt Holdings Inc - Ordinary Shares - Class A

Bakkt Holdings Inc

Bakkt is trending due to a broader crypto market rally and recent strategic restructuring, including the sale of its loyalty business and appointment of a fintech veteran to its board. The community is actively discussing the potential for a short squeeze and the company's transformation into a pure-play digital asset platform. Bullish sentiment is growing, with some eyeing prior highs and speculating about future partnerships and expansion.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

CRCL is trending due to a mix of positive price action and news of increased competition in the stablecoin space. Community members are debating whether the stock will continue its upward momentum or face a pullback due to potential rate cuts impacting revenue. Traders are actively discussing technical levels and potential short squeezes, with some highlighting the impact of insider selling and upcoming share unlock.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as investors discuss potential catalysts, including upcoming data presentations at the World Muscle Society (WMS) Congress and the anticipation of positive news regarding SRP-9003. Community members are weighing the potential for a short squeeze given the stock's high short interest, with some expressing optimism for a significant price increase and buyout speculation, while remaining cautiously optimistic.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

RDDT is trending downwards as the community debates the impact of AI, particularly ChatGPT potentially reducing its reliance on Reddit content for training and responses. This news has sparked discussions about the stock's valuation and future growth prospects, with some traders viewing the dip as a buying opportunity while others anticipate further declines. Chatter also revolves around short squeezes, potential government contracts through RUM, and potential partnerships in the AI space.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the community anticipates potential ETF approvals and discusses the implications of David Schwartz stepping down as CTO.  Bullish sentiment is fueled by discussions around institutional adoption, tokenization, and cross-border payment utility, with some speculating on significant price movement.  Despite positive news, XRP struggles to break the $3 mark, leading to frustration and debate about market manipulation and future potential.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

Occidental Petroleum is trending as investors react to Berkshire Hathaway's acquisition of OXY's OxyChem unit, leading to discussions around debt reduction and potential share buybacks. Community perspectives are mixed, with some questioning the strategic rationale behind selling a profitable business unit while others see it as a necessary step to strengthen the balance sheet. The news has sparked debate about the company's future direction and exposure to oil price fluctuations.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USAR is experiencing increased attention, with community members citing a potential breakout and government investment possibilities as catalysts. Discussions revolve around recent news, high call option activity, and the significance of rare earth elements for national security. The stock's breakout is leading to speculation about future price targets and institutional interest.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla's Q3 delivery numbers beat estimates, but the stock is down, sparking debate on whether this was a "sell the news" event or a sign of concerns about future growth and the end of EV tax credits; the community is actively discussing potential support levels and the impact of Elon Musk's actions on the stock.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Can Galafold Drive Amicus' Growth Through the Rest of 2025?

Galafold's steady growth, rising sales and strong patent protection position Amicus for continued growth and momentum through 2025.

Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline 

Kymera advances its protein degradation pipeline with new Sanofi and Gilead deals, milestone payouts, and promising trial updates.

Novavax, Inc. (NVAX) on Tuesday said that it has amended its collaboration and license agreement with Sanofi (SNY) to include the use of its Matrix-M adjuvant in Sanofi's pandemic influenza vaccine candidate program.The amendment of the agreement allows for the use of Matrix-M in early-stage development of Sanofi's pandemic influenza vaccine candidate. The two players will negotiate license rates and financial terms if the program enters late-stage study, Novavax <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.novavax.com/press-releases/2025-09-30-Novavax-Announces-Progress-on-Sanofi-Agreement">said</a>.Matrix-M is Novavax's proprietary adjuvant that can be added to a vaccine to stimulate a stronger immune response and is currently used in globally approved vaccines. Sanofi is currently exploring additional opportunities with Matrix-M, Novavax said.<a href="https://stocktwits.com/symbol/NVAX">NVAX stock</a> traded 1.4% lower on Tuesday morning and was among the top trending tickers on Stocktwits. On Stocktwits, retail sentiment around NVAX stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.A Stocktwits user opined that the agreement is a long-term payout play.<stembedurl>https://stocktwits.com/DifferentRadar/message/630462629</stembedurl>The new amendment adds to the terms of the original agreement between the two companies, dated May 2024. Under the agreement, Novavax is entitled to receive up to $200 million for the first four products created by Sanofi utilizing its Matrix-M adjuvant, and up to $210 million in milestone payments for each product including Matrix-M thereafter. Novavax is also eligible to receive royalties for all Sanofi products utilizing Matrix-M.Sanofi is Novavax’s biggest partner. In the second quarter, the $199 million received from Sanofi accounted for over 83% of Novavax’s total revenue of $239 million.NVAX stock is up by 5% this year but down by 33% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-gets-price-target-hike-from-canaccord/chDD7JrR3Bq">Tesla Gets A Price Target Hike From Canaccord: Retail Sees Stock Touching New Highs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration a covid-19 vaccine is seen with the Novavax logo in the background. (Photo Illustration by Nikos Pekiaridis/NurPhoto via Getty Images)

Novavax Amends Deal With Sanofi, Broadens Partnership

The amendment of the agreement allows for the use of Matrix-M in early-stage development of Sanofi's pandemic influenza vaccine candidate.

Equity

The amendment of the agreement allows for the use of Matrix-M in early-stage development of Sanofi's pandemic influenza vaccine candidate.


Can RIGL's Oncology Portfolio Create Long-Term Value Beyond Tavalisse?

Rigel's Tavalisse drives strong sales, but expansion with Rezlidhia, Gavreto, and pipeline candidates could shape its long-term growth story.

FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza 

Regeneron wins FDA approval to extend Evkeeza use in children as young as one with severe familial hypercholesterolemia.

RIGL vs. FOLD: Which Biotech Stock Offers Better Growth Potential?

Rigel and Amicus are advancing rare disease therapies, with rising sales from key drugs fueling growth prospects in 2025.

Shares of Immuneering Corp. rose 42% in after-hours trading on Wednesday after the company’s Phase 2a trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel showed an 86% overall survival rate in patients with first-line pancreatic cancer at nine months, compared with a 47% benchmark for standard of care.The stock closed Wednesday’s regular session up 7.5% at $9.23.Immuneering said it plans to seek regulatory feedback on its pivotal trial plans in the fourth quarter and, subject to that feedback, aims to launch a Phase 3 trial of atebimetinib plus mGnP by the end of 2025, with patient dosing to begin by mid-2026.&nbsp;The company also expects to initiate additional atebimetinib clinical trial combination arms in 2026, including in non-small cell lung cancer.Progression-free survival at nine months was 53%, compared to a 29% benchmark for standard of care. At six months, overall survival was 94%, and progression-free survival was 70%, both&nbsp;rates exceeding&nbsp;historical benchmarks. Median overall survival has not yet been reached.The treatment was generally well-tolerated. The serious side effects,&nbsp;observed in more than 1 in 10 people, included low white blood cell counts, which can increase the risk of infection, and anemia, characterized by low red blood cell levels. No new safety concerns were identified.CEO Ben Zeskind said the nine-month overall survival data widened the gap against&nbsp;the standard of care, describing the results as “extraordinary.” Chief Scientific Officer Brett Hall said atebimetinib, designed as a Deep Cyclic Inhibitor, represents a “fundamental shift in targeted therapy.”&nbsp;Vincent Chung, principal investigator of the trial at City of Hope, said the results mark “an important step” toward urgently needed new treatment options for pancreatic cancer, adding that the company is also planning a confirmatory study.&nbsp;Separately, Immuneering announced a proposed underwritten public offering of its Class A common stock, or in lieu of stock, pre-funded warrants. The company also stated that Sanofi agreed to purchase $25 million of shares in a concurrent private placement at the public offering price, with both transactions expected to close simultaneously.&nbsp;Immuneering plans to use the proceeds to advance the development of its drug candidates and for general corporate purposes.On Stocktwits, retail sentiment for Immuneering was ‘extremely bullish’ amid a 3,540% surge in 24-hour message volume, placing it among the top 10 trending equities on the platform.&nbsp;One user said the offering “didn’t completely kill the momentum,” adding that it gave them hope for the next trading day.&nbsp;<stembedurl>https://stocktwits.com/Mushichka/message/629894873</stembedurl>Another user said they were in “for the long haul, which now extends into mid-2026,” and added that the stock offering would likely be shrugged off within a day before analysts begin calculating Immuneering’s valuation based on potential sales of what they described as the gold standard for treating pancreatic cancer.<stembedurl>https://stocktwits.com/OptimistJP/message/629894127</stembedurl><a href="https://stocktwits.com/symbol/IMRX">Immuneering’s stock</a> has surged 320% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Immuneering’s stock (IMRX) has surged 320% so far in 2025. (Photo credit: Getty Images)

Why Immuneering Stock Soared Over 40% After-Hours Today

Updated trial data showed its drug atebimetinib nearly doubled survival benchmarks in first-line pancreatic cancer, with the company planning a pivotal Phase 3 study by late 2025.

SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU

Sanofi/Regeneron's Dupixent wins CHMP backing for chronic spontaneous urticaria in the EU, paving the way for expanded treatment options.

FDA Extends Review Period of Sanofi's Multiple Sclerosis Drug Filing

The FDA extends SNY's tolebrutinib NDA review by three months, with decision now expected on Dec. 28, 2025.

Rigel Gains 77% in 3 Months: Is This an Indication to Buy the Stock?

RIGL shares surge 77% in three months as Tavalisse drives record sales along with other products while boosting the company's 2025 outlook.

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

Sanofi - ADR

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

SNY
Sanofi-Aventis

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SNY News

SNY Sanofi-Aventis